Table 3 Post hoc analyses of the primary and key secondary efficacy outcomes in Chinese patients
Placebo (n = 72) | Eptinezumab 100 mg (n = 65) | |
|---|---|---|
Primary endpoint | ||
Change from baseline in MMDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.6 (0.71) | -7.1 (0.75) |
Difference from placebo (95% CI) | -1.4 (-3.5 to 0.6) | |
p-value vs placebo | 0.1584 | |
Key secondary endpoints | ||
Changes from baseline in MMDs with AHM (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.8 (0.72) | -7.4 (0.76) |
Difference from placebo (95% CI) | -1.6 (-3.7 to 0.4) | |
p-value vs placebo | 0.1216 | |
≥ 50% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 16/72 (22.2) | 21/65 (32.3) |
Difference to placebo (%) | 10.1 | |
Odds ratio vs placebo (95% CI) | 1.75 (0.81 to 3.87) | |
p-value vs placebo | 0.1563 | |
Migraine rate on the day after dosing (Day 1) | ||
Baseline, n (%) | 72 (69.0) | 65 (70.9) |
Day 1, n (%) | 71 (57.1) | 65 (42.0) |
p-value vs placebo | 0.0612 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–4), n/N (%) | 1/71 (1.4) | 13/65 (20.0) |
Difference to placebo (%) | 18.6 | |
Odds ratio vs placebo (95% CI) | 20.12 (3.68 to 378.87) | |
p-value vs placebo | < .0001 | |
Change from baseline in the number of MHDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.6 (0.70) | -7.0 (0.74) |
Difference from placebo (95% CI) | -1.5 (-3.5 to 0.6) | |
p-value vs placebo | 0.1548 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 1/72 (1.4) | 12/65 (18.5) |
Difference to placebo (%) | 17.1 | |
Odds ratio vs placebo (95% CI) | 19.04 (3.44 to 359.04) | |
p-value vs placebo | 0.0001 | |